Concord Wealth Partners Crispr Therapeutics Ag Transaction History
Concord Wealth Partners
- $559 Million
- Q2 2024
A detailed history of Concord Wealth Partners transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Concord Wealth Partners holds 20 shares of CRSP stock, worth $939. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20
Previous 31
35.48%
Holding current value
$939
Previous $2,000
50.0%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding CRSP
# of Institutions
523Shares Held
58MCall Options Held
1.73MPut Options Held
1.84M-
Capital International Investors Los Angeles, CA7.87MShares$370 Million0.09% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.78MShares$366 Million3.82% of portfolio
-
Nikko Asset Management Americas, Inc.3.15MShares$148 Million1.99% of portfolio
-
Sumitomo Mitsui Trust Holdings, Inc.3.15MShares$148 Million0.13% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$131 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.67B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....